News
The data could help the Enhertu regimen overtake a drug combination that’s been used as the initial treatment for ...
Enhertu plus Perjeta demonstrated improvement in progression-free survival versus standard treatment in HER2-positive ...
3d
GlobalData on MSNDaiichi and AstraZeneca’s Enhertu shows PFS benefits in breast cancer trialThe trial aims to assess the safety and efficacy of Enhertu, either as a single agent or with pertuzumab, against the THP.
AstraZeneca and Daiichi Sankyo are aiming to establish their star antibody-drug conjugate (ADC) Enhertu as a first-line ...
AstraZeneca's Enhertu shows significant success in late-stage trials as a first-line treatment for HER2-positive metastatic ...
Analysts at Leerink Partners said in a Monday note that DESTIN-Breast09’s findings “could support an approval” for Enhertu in ...
Enhertu is already approved as a second-line or later therapy for HER2-positive breast cancer based on the results of the ...
In the Phase III DESTINY-Breast09 trial, Enhertu (trastuzumab deruxtecan) and Perjeta (pertuzumab) significantly improved ...
Daiichi Sankyo seeks Japanese approval for Enhertu to treat patients with HER2 positive metastatic solid tumours: Tokyo Friday, April 25, 2025, 09:00 Hrs [IST] Daiichi Sankyo has ...
Daiichi Sankyo Co., Ltd. (TSE:4568) shares surged 6.2% after the pharmaceutical company announced robust fourth-quarter earnings that surpassed expectations, coupled with a significant share buyback ...
DESTINY-Breast09 Phase III trial of AstraZeneca (AZN) and Daiichi Sankyo’s ENHERTU is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results